A network meta-analysis of the association between patient traits and response to regular dosing with ICS/long-acting β2-agonist plus short-acting β2 agonist reliever or maintenance and reliever therapy for asthma

Simple item page
dc.contributor.authorYorgancıoğlu A.
dc.contributor.authorCruz A.A.
dc.contributor.authorGarcia G.
dc.contributor.authorLavoie K.L.
dc.contributor.authorRoche N.
dc.contributor.authorAbhijith P.G.
dc.contributor.authorVerma M.
dc.contributor.authorMajumdar A.
dc.contributor.authorChatterjee S.
dc.date.accessioned2024-07-22T08:02:20Z
dc.date.available2024-07-22T08:02:20Z
dc.date.issued2023
dc.description.abstractIntroduction: Current treatment for moderate–severe asthma with inhaled corticosteroid (ICS)-based therapy can follow two strategies: a single inhaler maintenance and reliever therapy (MART) regimen, or regular dosing with ICS/long-acting β2-agonist used as maintenance therapy plus a separate short acting β2-agonist reliever inhaler. It would be clinically useful to understand the potential of patient traits to influence regular dosing or MART treatment outcomes. Objectives: A systematic literature review (SLR) and meta-analysis was conducted to identify specific patient traits that may predict improved clinical outcomes with regular dosing or MART. Results: The SLR identified 28 studies in patients with moderate–severe asthma assessing regular dosing or MART treatments and reporting the traits and outcomes of interest. Network meta-regressions found no significant difference in the relative efficacy of regular dosing as compared with MART on any of the clinical outcomes (exacerbation rate, time to first exacerbation, FEV1, reliever use and adherence) for any of the patient traits (baseline lung function, baseline ACQ, age, BMI, and smoking history) evaluated. However, some trends towards traits influencing treatment efficacy were identified. Inconsistent reporting of traits and outcomes was observed between trials. Conclusions: The analysed patient traits evaluated in this study were associated with similar efficacy for the analysed outcomes to either regular dosing or MART; however, trends from the data observed encourage future analyses for possible identification of additional traits, or a combination of traits, that may be of interest. More comparable reporting of clinically important traits and outcomes would improve future analyses. © 2023 The Authors
dc.identifier.DOI-ID10.1016/j.rmed.2023.107377
dc.identifier.issn09546111
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11810
dc.language.isoEnglish
dc.publisherW.B. Saunders Ltd
dc.rightsAll Open Access; Hybrid Gold Open Access
dc.subjectAdministration, Inhalation
dc.subjectAdrenal Cortex Hormones
dc.subjectAnti-Asthmatic Agents
dc.subjectAsthma
dc.subjectBudesonide
dc.subjectEthanolamines
dc.subjectFormoterol Fumarate
dc.subjectHumans
dc.subjectNetwork Meta-Analysis
dc.subjectbeclometasone
dc.subjectbeta 2 adrenergic receptor stimulating agent
dc.subjectlong acting drug
dc.subjectshort acting drug
dc.subjectantiasthmatic agent
dc.subjectbudesonide
dc.subjectcorticosteroid
dc.subjectethanolamine derivative
dc.subjectformoterol fumarate
dc.subjectadult
dc.subjectArticle
dc.subjectasthma
dc.subjectAsthma Control Questionnaire
dc.subjectattrition bias
dc.subjectbody mass
dc.subjectclinical feature
dc.subjectclinical outcome
dc.subjectcomparative effectiveness
dc.subjecteosinophil count
dc.subjectfemale
dc.subjectforced expiratory volume
dc.subjecthuman
dc.subjectlung function
dc.subjectmaintenance therapy
dc.subjectmale
dc.subjectmedication compliance
dc.subjectmeta analysis
dc.subjectnetwork meta-analysis
dc.subjectoutcome assessment
dc.subjectpatient compliance
dc.subjectperformance bias
dc.subjectrace
dc.subjectsevere asthma
dc.subjectsmoking
dc.subjectstatistically significant result
dc.subjectsystematic review
dc.subjectinhalational drug administration
dc.subjectnetwork meta-analysis
dc.titleA network meta-analysis of the association between patient traits and response to regular dosing with ICS/long-acting β2-agonist plus short-acting β2 agonist reliever or maintenance and reliever therapy for asthma
dc.typeArticle

Files

Collections

Scopus Koleksiyonu